Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 183   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

Year : 2010  |  Volume : 1  |  Issue : 3  |  Page : 297-301 Table of Contents     

Male hypogonadism: Symptoms and treatment

SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya,Bilaspur -495 009 (C.G), India

Date of Web Publication10-Nov-2010

Correspondence Address:
Peeyush Kumar
SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur - 495 009 (C.G)
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0110-5558.72420

Rights and Permissions

Male hypogonadism is a condition in which the body does not produce enough of the testosterone hormone; the hormone that plays a key role in masculine growth and development during puberty. There is a clear need to increase the awareness of hypogonadism throughout the medical profession, especially in primary care physicians who are usually the first port of call for the patient. Hypogonadism can significantly reduce the quality of life and has resulted in the loss of livelihood and separation of couples, leading to divorce. It is also important for doctors to recognize that testosterone is not just a sex hormone. There is an important research being published to demonstrate that testosterone may have key actions on metabolism, on the vasculature, and on brain function, in addition to its well-known effects on bone and body composition. This article has been used as an introduction for the need to develop sensitive and reliable assays for sex hormones and for symptoms and treatment of hypogonadism.

Keywords: Male hypogonadism, pituitary, sex hormone, testosterone, testis

How to cite this article:
Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res 2010;1:297-301

How to cite this URL:
Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res [serial online] 2010 [cited 2023 Feb 9];1:297-301. Available from: https://www.japtr.org/text.asp?2010/1/3/297/72420

   Introduction Top

Hypogonadism is a medical term for decreased functional activity of the gonads. The gonads (ovaries or testes) produce hormones (testosterone, estradiol, antimullerian hormone, progesterone, inhibin B, activin) and gametes (eggs or sperm). [1] Male hypogonadism is characterized by a deficiency in testosterone - a critical hormone for sexual, cognitive, and body function and development. Clinically low testosterone levels can lead to the absence of secondary sex characteristics, infertility, muscle wasting, and other abnormalities. Low testosterone levels may be due to testicular, hypothalamic, or pituitary abnormalities. In individuals who also present with clinical signs and symptoms, clinical guidelines recommend treatment with testosterone replacement therapy.

   Classification of Male Hypogonadism Top

There are two basic types of hypogonadism that exist:

Primary: This type of hypogonadism - also known as primary testicular failure - originates from a problem in the testicles.

Secondary: This type of hypogonadism indicates a problem in the hypothalamus or the pituitary gland - parts of the brain that signal the testicles to produce testosterone. The hypothalamus produces the gonadotropin releasing hormone, which signals the pituitary gland to make the follicle-stimulating hormone (FSH) and luteinizing hormone. The luteinizing hormone then signals the testes to produce testosterone. Either type of hypogonadism may be caused by an inherited (congenital) trait or something that happens later in life (acquired), such as an injury or an infection.

Primary Hypogonadism

Common causes of primary hypogonadism include:

Klinefelter's Syndrome: This condition results from a congenital abnormality of the sex chromosomes, X and Y. A male normally has one X and one Y chromosome. In Klinefelter's syndrome, two or more X chromosomes are present in addition to one Y chromosome. The Y chromosome contains the genetic material that determines the sex of a child and the related development. The extra X chromosome that occurs in Klinefelter's syndrome causes abnormal development of the testicles, which in turn results in the underproduction of testosterone.

Undescended testicles

Before birth, the testicles develop inside the abdomen and normally move down into their permanent place in the scrotum. Sometimes, one or both of the testicles may not descend at birth. This condition often corrects itself within the first few years of life without treatment. If not corrected in early childhood, it may lead to malfunction of the testicles and reduced production of testosterone.

Mumps orchitis

If a mumps infection involving the testicles in addition to the salivary glands (mumps orchitis) occurs during adolescence or adulthood, long-term testicular damage may occur. This may affect normal testicular function and testosterone production.


Too much iron in the blood can cause testicular failure or pituitary gland dysfunction, affecting testosterone production.

Injury to the Testicles

Because of their location outside the abdomen, the testicles are prone to injury. Damage to normally developed testicles can cause hypogonadism. Damage to one testicle may not impair testosterone production.

Cancer treatment

Chemotherapy or radiation therapy for the treatment of cancer can interfere with testosterone and sperm production. The effects of both treatments are often temporary, but permanent infertility may occur. Although many men regain their fertility within a few months after the treatment ends, preserving sperm before starting cancer therapy is an option that many men consider. Howell et al. reported that hypogonadism was seen in 30% of the men with cancer and 90% of these gentlemen had germinal epithelial failure. [2]

Normal aging

Older men generally have lower testosterone levels than younger men do. As men age, there's a slow and continuous decrease in testosterone production. The rate that testosterone declines varies greatly among men. As many as 30% of men older than 75 have a testosterone level that is below normal, according to the American Association of Clinical Endocrinologists. Whether or not treatment is necessary remains a matter of debate. [3]

Secondary Hypogonadism

In secondary hypogonadism, the testicles are normal, but function improperly due to a problem with the pituitary or hypothalamus. A number of conditions can cause secondary hypogonadism, including:

Kallmann syndrome

Abnormal development of the hypothalamus - the area of the brain that controls the secretion of pituitary hormones - can cause hypogonadism. This abnormality is also associated with the impaired development of the ability to smell (anosmia).

Pituitary disorders

An abnormality in the pituitary gland can impair the release of hormones from the pituitary gland to the testicles, affecting normal testosterone production. A pituitary tumor or other type of brain tumor located near the pituitary gland may cause testosterone or other hormone deficiencies. Also, the treatment for a brain tumor such as surgery or radiation therapy may impair pituitary function and cause hypogonadism.

Inflammatory disease

Certain inflammatory diseases such as sarcoidosis, Histiocytosis, and tuberculosis involve the hypothalmus and pituitary gland and can affect testosterone production, causing hypogonadism.


This virus can cause low levels of testosterone by affecting the hypothalamus, the pituitary, and the testes.


The use of certain drugs, such as, opiate pain medications and some hormones, can affect testosterone production. [4]


Being significantly overweight at any age may be linked to hypogonadism.

Stress-induced Hypogonadism

Stress, excessive physical activity, and weight loss have all been associated with hypogonadism. Some have attributed this to stress-induced hypercortisolism, which would suppress hypothalamic function. [5]

   Role of Testosterone Top

Throughout the male lifespan, testosterone plays a critical role in sexual, cognitive, and body development. During fetal development, testosterone aids in the determination of sex. The most visible effects of rising testosterone levels begin in the prepubertal stage. During this time, body odor develops, oiliness of the skin and hair increase, acne develops, accelerated growth spurts occur, and pubic, early facial, and axillary hair grows. In men, the pubertal effects include enlargement of the sebaceous glands, penis enlargement, increased libido, increased frequency of erections, increased muscle mass, deepening of voice, increased height, bone maturations, loss of scalp hair, and growth of facial, chest, leg, and axillary hair. Even as adults, the effects of testosterone are visible as libido, penile erections, aggression, and mental and physical energy.

Pathophysiology of Testosterone and Hypogonadism

The cerebral cortex - the layer of the brain often referred to as the gray matter - is the most highly developed portion of the human brain. This portion of the brain, encompassing about two-thirds of the brain mass, is responsible for the information processing in the brain. It is within this portion of the brain that testosterone production begins. The cerebral cortex signals the hypothalamus to stimulate production of testosterone. To do this, the hypothalamus releases the gonadotropin-releasing hormone in a pulsatile fashion, which stimulates the pituitary gland - the portion of the brain responsible for hormones involved in the regulation of growth, thyroid function, blood pressure, and other essential body functions. Once stimulated by the gonadotropin-releasing hormone, the pituitary gland produces the follicle-stimulating hormone and the luteinizing hormone. Once released into the bloodstream, the luteinizing hormone triggers activity in the Leydig cells in the testes. In the Leydig cells, cholesterol is converted to testosterone. When the testosterone levels are sufficient, the pituitary gland slows the release of the luteinizing hormone via a negative feedback mechanism, thereby, slowing testosterone production. With such a complex process, many potential problems can lead to low testosterone levels. Any changes in the testicles, hypothalamus or pituitary gland can result in hypogonadism. Such changes can be congenital or acquired, temporary, or permanent.

Recent studies have found that testosterone production slowly decreases as a result of aging, although the rate of decline varies. Unlike women who experience a rapid decline in hormone levels during menopause, men experience a slow, continuous decline over time. The Baltimore Longitudinal Study of Aging reported that approximately 20% of men in their 60s and 50% of men in their 80s are hypogonadal. [6] The New Mexico Aging Process Study showed a decrease in serum testosterone of 110 ng/dL every 10 years. [7] As hormone levels decline slowly, this type of hypogonadism is sometimes referred to as the partial androgen deficiency of the aging male (PADAM). With the growing elderly population, the incidence of PADAM may increase over the next few decades.

Regardless of the age or comorbid conditions, obesity is associated with hypogonadism. The Baltimore Longitudinal Study of Aging found that testosterone decreased by 10 ng/dL per 1-kg/m 2 increase in body mass index. [6] Another study also showed reduced testosterone levels in men with increased total abdominal adiposity. [8] The proposed causes for the effects of obesity on testosterone level include increased clearance or aromatization of testosterone in the adipose tissue and increased formation of inflammatory cytokines, which hinder the secretion of the gonadotropin-releasing hormone. [9] Similar to the projections for an aging population, the increasing incidence of obesity may lead to an increased incidence of secondary hypogonadism. When the risk factors of obesity and age are removed, diabetes mellitus still remains an independent risk factor for hypogonadism. Although diabetes mellitus-related hypogonadism was previously thought to be associated with testicular failure, study results show one-third of diabetic men had low testosterone levels, but also had low pituitary hormone levels. [10] Population projections expect the number of cases of diabetes mellitus to rise from 171 million in 2000 to 366 million in 2030. [11] This drastic increase in cases will impact the prevalence of hypogonadism as well. Certain medications are shown to reduce testosterone production. Among the medications known to alter the hypothalamic-pituitary-gonadal axis are spironolactone, corticosteroids, ketoconazole, ethanol, anticonvulsants, immunosuppressants, opiates, psychotropic medications, and hormones.


Hypogonadism is characterized by serum testosterone levels < 300 ng/dL in combination with at least one clinical sign or symptom. Signs of hypogonadism include absence or regression of secondary sex characteristics, anemia, muscle wasting, reduced bone mass or bone mineral density, oligospermia, and abdominal adiposity. Symptoms of post pubescent hypogonadism include sexual dysfunction (erectile dysfunction, reduced libido, diminished penile sensation, difficulty attaining orgasm, and reduced ejaculate), reduced energy and stamina, depressed mood, increased irritability, difficulty concentrating, changes in cholesterol levels, anemia, osteoporosis, and hot flushes. In the prepubertal male, if treatment is not initiated, signs and symptoms include sparse body hair and delayed epiphyseal closure.


Early diagnosis and treatment can reduce risks associated with hypogonadism. Early detection in young boys can help to prevent problems due to delayed puberty. Early diagnosis in men helps protect against the development of osteoporosis and other conditions. The diagnosis of hypogonadism is based on symptoms and blood work, particularly on testosterone levels. Often the first step toward diagnosis is the Androgen Deficiency in Aging Male (ADAM) test - a 10 item questionnaire intended to identify men who exhibit signs of low testosterone. Testosterone levels vary throughout the day and are generally highest in the morning, so blood levels are typically drawn early in the morning. If low testosterone levels are confirmed, further testing is done, to identify if the cause is testicular, hypothalamic, or pituitary. These tests may include hormone testing, semen analysis, pituitary imaging, testicular biopsy, and genetic studies. Once the treatment starts, the patient may continue to have testosterone levels drawn to determine if the medication is helping to produce adequate testosterone levels.

   Treatment Options Top

Testosterone replacement therapy is the primary treatment option for hypogonadism. Ideally, the therapy should provide physiological testosterone levels, typically in the range of 300 to 800 ng/dL. According to the guidelines from the American Association of Clinical Endocrinologists, [12] updated in 2002, the goals of therapy are to:

  1. Restore sexual function, libido, well-being, and behavior
  2. Produce and maintain virilization
  3. Optimize bone density and prevent osteoporosis
  4. In elderly men, possibly normalize growth hormone levels
  5. Potentially affect the risk of cardiovascular disease
  6. In cases of hypogonadotropic hypogonadism, restore fertility [13]

To achieve these goals, several testosterone delivery systems are currently available in the market. Clinical guidelines published in 2006, by the Endocrine Society, recommend reserving treatment for those patients with clinical symptoms, rather than for those with just low testosterone levels.

Transdermal Patch

Transdermal testosterone patches are available in India under the brand name Androderm. Transdermal patches deliver continuous levels of testosterone over a 24-hour period. Application site reactions account for the majority of adverse effects associated with transdermal patches, with elderly men proving particularly prone to skin irritation. Local reactions include pruritus, blistering under the patch, erythema, vesicle formation, indurations, and allergic contact dermatitis. Approximately 10% of the patients discontinue patch therapy due to skin reactions. [14] In one study, 60% of the subjects discontinued the patch between weeks four and eight due to skin irritation. [15] A small percentage of patients may also experience headache, depression, and gastrointestinal (GI) bleeding. Some patients report that the patch easily falls off and is difficult to remove from the package without good dexterity. Transdermal patches are more expensive than injections, but the convenience of use and maintenance of normal diurnal testosterone levels are advantageous. Some patients report that the patch is noisy and therefore they feel stigmatized by its presence.

Topical Gel

Currently, two topical testosterone gels - Androgel and Testim, are available in India. Application in the morning allows for testosterone concentrations that follow the normal circadian pattern. Topical testosterone gels also provide longer-lasting elevations in serum testosterone, compared to transdermal patches. [16] Similar to patches, testosterone delivered via gels does not undergo first-pass metabolism. Adverse effects associated with therapy include headache, hot flushes, insomnia, increased blood pressure, acne, emotional labiality, and nervousness. Although application site reactions occur, skin irritation is approximately 10 times less frequent with gels than with transdermal patches. [17] Advantages associated with topical gel include maintenance of normal diurnal testosterone levels and documented increases in bone density. [18] Potential problems associated with the gel are the potential for transfer of the gel from person to person and the cost.

Buccal Tablets

Buccal testosterone tablets, marketed as Striant, release testosterone in a pulsatile manner, are similar to endogenous secretion. With this route, the peak testosterone levels are rapidly achieved and a steady state is reached by the second dose following twice-daily dosing. Similar to gel and transdermal products, buccal administration avoids first-pass metabolism. Food and beverage do not alter drug absorption. Although well-tolerated, transient gum irritation and a bitter taste are the chief adverse effects associated with this route. Gum irritation tends to resolve within the first week. Other adverse effects include dry mouth, toothache, and stomatitis. Some patients find the buccal tablet uncomfortable and report concern about the tablet shifting in the mouth while talking.

Implantable Pellet

Testosterone has also been formulated into an implantable pellet, marketed as Testopel. This surgically implanted pellet slowly releases testosterone via zero-order kinetics over many months (up to six months), although peak testosterone levels are achieved within 30 minutes. The chief complaints associated with this formulation are pellet extrusion, minor bleeding, and fibrosis at the site.

Intramuscular Injections

Intramuscular formulations are also available, sold as Depo-Testosterone (testosterone cypionate) and Delatestryl (testosterone enanthate). The testosterone is suspended in oil to prolong absorption. Peak levels occur within 72 hours of administration, but intramuscular administration is associated with the most variable pharmacokinetics of all the formulations. In the first few days after administration, supraphysiological testosterone levels are achieved, followed by subphysiological levels near the end of the dosing interval. Such fluctuations, are often associated with wide variations in mood, energy, and sexual function, and prove distressing to many patients. To reduce fluctuations, lower doses and shorter dosing intervals (two weeks) are often used. Injection site reactions are also common, but are rarely the reason for discontinuation of therapy. Despite the fluctuations in testosterone levels, intramuscular injections provide a cost-effective option and the convenience of two- to four-week dosing intervals. Disadvantages associated with injections include visits to the doctor's office, visits for dose administration, and lack of physiological testosterone patterns.

Oral Tablets

Although not currently available in the India, oral testosterone tablets, under the brand name Andriol, are available in other countries. In India, Android and Testroid - both methyl testosterone products are FDA approved oral formulations. Although relatively inexpensive, oral products undergo extensive first-pass metabolism and therefore require multiple daily doses. Oral products are associated with elevated liver enzymes, GI intolerance, acne, and gynecomastia. Regardless of the treatment option, patients should be aware of the risks associated with testosterone therapy, including:

  • Worsening of the prostatic hypertrophy
  • Increased risk of prostate cancer
  • Lower sperm count with large doses
  • Swelling of ankles, feet, or body, with or without heart failure
  • Gynecomastia
  • Sleep apnea
  • Blood clots

Patients should be educated on the signs and symptoms of these adverse effects and instructed to notify their doctor if any of these occur.

   Conclusion Top

Hypogonadism affects men of all ages, either through congenital or acquired causes. For patients who have clinical symptoms associated with their low testosterone levels, treatment is essential for the prevention of sexual, cognitive, and bodily changes. A variety of treatment options are available, utilizing different dosage formulations, and providing patients with choices that best meet their needs. Therefore, there is a clear need to increase the awareness of hypogonadism throughout the medical profession, especially in primary care physicians who are usually the first port of call for the patient.

In summary, there is a need for doctors to have an awareness of hypogonadism as a common clinical condition. Key triggers for the physician to consider investigating for hypogonadism are reduced libido, fatigue, osteoporosis and fractures, and erectile dysfunction.

   References Top

1.Yialamas MA, Hayes FJ. Androgens and the ageing male and female. J Clin Endocrinol Metab 2003;17:223-36.  Back to cited text no. 1
2.Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: Evidence of leydig cell insufficiency. J Clin Oncol 1999;17:1493-8.  Back to cited text no. 2
3.Harman SM. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.  Back to cited text no. 3
4.Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377-84.  Back to cited text no. 4
5.Cumming DC, Quigley ME, Yen SS. Acute suppression of circulating testosterone levels by cortisol in men. J Clin Endocrinol Metab 1983;57:671-3.  Back to cited text no. 5
6.Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.  Back to cited text no. 6
7.Morley JE, Kaiser FE, Perry HM. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-3.  Back to cited text no. 7
8.Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993;17:643-9.  Back to cited text no. 8
9.Zumoff B, Strain GW, Miller LK. Plasma free and non-sex-hormone-binding globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929-31.  Back to cited text no. 9
10.Dhindsa S, Prabhaker S, Sethi M, Bandyopadhyay A, Chaudhari A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-8.  Back to cited text no. 10
11.Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.  Back to cited text no. 11
12.AACE Hypogonadism Task Force. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients -2002 updated. Endocr Pract 2002;8:434-56.  Back to cited text no. 12
13.Bhasin S, Cunningham GR, Hayes FJ. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.  Back to cited text no. 13
14.Jordan JR. Allergy and topical irritation associated with transdermal testosterone administration: A comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermatol 1997;8:108-13.  Back to cited text no. 14
15.Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol (Oxf) 1999;50:57-62.  Back to cited text no. 15
16.Swerdloff RS, Wang C, Cunningham G. Long-term pharmacokinetics of transdermal testosterone gal in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10.  Back to cited text no. 16
17.Wang C, Swedloff RS, Iranmanesh A.Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypgonadal men. J Clin Endocrinol Metab 2000;85:2839-53.  Back to cited text no. 17
18.Wang C, Swerdloff RS, Iranmanesh A. Effects of transdermal testosterone gel on bone turnover makers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001;54:739-50.  Back to cited text no. 18

This article has been cited by
1 Schisandrol A and gomisin N from Schisandra chinensis extract improve hypogonadism via anti-oxidative stress in TM3 Leydig cells
Jia Bak, Seung Ju Lee, Tae Won Kim, Seonhwa Hwang, Min Ju Park, Rohith Arunachalam, Eunsoo Yoo, Min Hi Park, Yun-Sik Choi, Hye Kyung Kim
Nutrition Research and Practice. 2023; 17(1): 1
[Pubmed] | [DOI]
2 Testosterone Improved Hyperalgesia in a Patient Under Methadone Maintenance Treatment
Nader Charkhgard, Shahram Naderi, Kamyar Ghani, Mahboubeh Manouchehrabadi
Archives of Neuroscience. 2022; 9(1)
[Pubmed] | [DOI]
3 Focus on Androgel ®
W Rabbets
South African General Practitioner. 2022; 3(1): 6
[Pubmed] | [DOI]
4 Hemorheological Alterations and Physical Activity
Ivan Ivanov
Applied Sciences. 2022; 12(20): 10374
[Pubmed] | [DOI]
5 The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity
Tiziana Siciliano, Ulrich Sommer, Alicia-Marie K. Beier, Matthias B. Stope, Angelika Borkowetz, Christian Thomas, Holger H. H. Erb
Current Issues in Molecular Biology. 2022; 44(2): 597
[Pubmed] | [DOI]
6 Predictors of testosterone in zoo-managed male African elephants (Loxodonta Africana)
Kaitlyn M. Campbell, James A. Wilson, Kari A. Morfeld
Zoo Biology. 2022;
[Pubmed] | [DOI]
7 Novel nandrolone aptamer for rapid colorimetric detection of anabolic steroids
Xhensila Shkembi, Mary Luz Botero, Vasso Skouridou, Miriam Jauset-Rubio, Marketa Svobodova, Pablo Ballester, Abdulaziz S. Bashammakh, Mohammad S. El-Shahawi, Abdulrahman O. Alyoubi, Ciara K. O'Sullivan
Analytical Biochemistry. 2022; 658: 114937
[Pubmed] | [DOI]
8 Safety of androgen therapy in men with prostate cancer
Mr Prabhakar Rajan, Tharu Tharakan, Runzhi Chen
Best Practice & Research Clinical Endocrinology & Metabolism. 2022; : 101628
[Pubmed] | [DOI]
9 Nonpharmacological Interventions for the Management of Testosterone and Sperm Parameters: A Scoping Review
Heitor O. Santos, Flávio A. Cadegiani, Scott C. Forbes
Clinical Therapeutics. 2022;
[Pubmed] | [DOI]
10 Association between ambient air pollution and blood sex hormones levels in men
Pai Zheng, Zhangjian Chen, Jiaqi Shi, Yuting Xue, Yi Bai, Yulin Kang, Huiyu Xu, Guang Jia, Tiancheng Wang
Environmental Research. 2022; : 113117
[Pubmed] | [DOI]
11 Leptin secreted from testicular microenvironment modulates hedgehog signaling to augment the endogenous function of Leydig cells
Himanshu Arora, Rehana Qureshi, Kajal Khodamoradi, Deepa Seetharam, Madhumita Parmar, Derek J. Van Booven, Isabelle Catherine Issa, Robert Sackstein, Dolores Lamb, Joshua M. Hare, Ranjith Ramasamy
Cell Death & Disease. 2022; 13(3)
[Pubmed] | [DOI]
12 Trends in testosterone prescription amongst medical specialties: a 5-year CMS data analysis
Isabelle V. Carter, Michael J. Callegari, Tarun K. Jella, Amr Mahran, Thomas B. Cwalina, Wade Muncey, Aram Loeb, Nannan Thirumavalavan
International Journal of Impotence Research. 2022;
[Pubmed] | [DOI]
13 The association between caffeine intake and testosterone: NHANES 2013–2014
Frank E. Glover, William Michael Caudle, Francesco Del Giudice, Federico Belladelli, Evan Mulloy, Eniola Lawal, Michael L. Eisenberg
Nutrition Journal. 2022; 21(1)
[Pubmed] | [DOI]
14 Association between hypertriglyceridemic waist phenotype and hypogonadism in Taiwanese adult men
Sheng-Kuang Wang, Meng-Chih Lee, Chia-Lien Hung, Hsin-Hung Chen, Chun-Cheng Liao, Yu-Lung Chiu, Giacomo Pucci
PLOS ONE. 2022; 17(3): e0265629
[Pubmed] | [DOI]
15 Reprotoxic activities of vildagliptin administration in male Wistar rats
Akinsomisoye Olumide Stephen, Owolabi Adegbenga Rotimi, Azeez Taoreed Adegoke, Osuntokun Opeyemi Samson
Brazilian Journal of Pharmaceutical Sciences. 2021; 57
[Pubmed] | [DOI]
16 Testosterone deficiency in men receiving immunotherapy for malignant melanoma
Madeline Peters,Amy Pearlman,William Terry,Sarah L. Mott,Varun Monga
Oncotarget. 2021; 12(3): 199
[Pubmed] | [DOI]
17 Morphological and transcriptomic alterations in neonatal lamb testes following developmental exposure to low-level environmental chemical mixture
Chris S. Elcombe,Ana Monteiro,Mohammad Ghasemzadeh-Hasankolaei,Neil P. Evans,Michelle Bellingham
Environmental Toxicology and Pharmacology. 2021; : 103670
[Pubmed] | [DOI]
18 The impact of testosterone on the QT interval: A Systematic review
Gilmar Gutierrez,Rachel Wamboldt,Adrian Baranchuk
Current Problems in Cardiology. 2021; : 100882
[Pubmed] | [DOI]
19 A Family with Novel X-linked recessive Homozygous mutation in ANOS-1 gene (c.628_629 del, p.1210fs*) in Kallmann syndrome associated unilateral ptosis; A case report and review of the literature.
Shahab Noorian,Shahram Savad,Armin Khavandegar,Mahnaz Jamee
AACE Clinical Case Reports. 2021;
[Pubmed] | [DOI]
20 Insights into the Regulation on Proliferation and Differentiation of Stem Leydig Cells
Zhuo-jie Liu,Yong-hui Liu,Sheng-yu Huang,Zhi-Jun Zang
Stem Cell Reviews and Reports. 2021;
[Pubmed] | [DOI]
21 The Usefulness of Sexual Behaviour Assessment at the Beginning of Service to Predict the Suitability of Boars for Artificial Insemination
Stanislaw Kondracki, Maria Iwanina, Anna Wysokinska, Dorota Banaszewska, Wladyslaw Kordan, Leyland Fraser, Katarzyna Rymuza, Krzysztof Górski
Animals. 2021; 11(12): 3341
[Pubmed] | [DOI]
22 Environmental Factors-Induced Oxidative Stress: Hormonal and Molecular Pathway Disruptions in Hypogonadism and Erectile Dysfunction
Shubhadeep Roychoudhury,Saptaparna Chakraborty,Arun Paul Choudhury,Anandan Das,Niraj Kumar Jha,Petr Slama,Monika Nath,Peter Massanyi,Janne Ruokolainen,Kavindra Kumar Kesari
Antioxidants. 2021; 10(6): 837
[Pubmed] | [DOI]
23 Improvement of Testicular Steroidogenesis Using Flavonoids and Isoflavonoids for Prevention of Late-Onset Male Hypogonadism
Luc J. Martin,Mohamed Touaibia
Antioxidants. 2020; 9(3): 237
[Pubmed] | [DOI]
24 Hypogonadism in Exercising Males: Dysfunction or Adaptive-Regulatory Adjustment?
Anthony C. Hackney
Frontiers in Endocrinology. 2020; 11
[Pubmed] | [DOI]
25 Various Factors May Modulate the Effect of Exercise on Testosterone Levels in Men
Ruba Riachy,Kevin McKinney,Demidmaa R. Tuvdendorj
Journal of Functional Morphology and Kinesiology. 2020; 5(4): 81
[Pubmed] | [DOI]
26 Advancements in the gold standard: Measuring steroid sex hormones by mass spectrometry
Steven E. Conklin,Claire E. Knezevic
Clinical Biochemistry. 2020;
[Pubmed] | [DOI]
27 Case Report of Transgender Patient with Gonadotropic Dysfunction Secondary to Craniopharyngioma: Toward Improving Understanding of Biopsychosocial Dynamics of Gender Identity in Neurosurgical Care
A. Scott Emmert,Ahmed E. Hussein,Olesia Slobodian,Bryan Krueger,Ruchi Bhabhra,Matthew C. Hagen,Sarah Pickle,Jonathan Forbes
World Neurosurgery. 2020;
[Pubmed] | [DOI]
28 Is it safe to delay testosterone replacement therapy in pandemic times?
Fernando Nestor Facio Junior,Luis Cesar Fava Spessoto
Revista da Associação Médica Brasileira. 2020; 66(suppl 2): 3
[Pubmed] | [DOI]
29 Yishentongluo decoction in treatment of idiopathic asthenozoospermia infertility
Qi Zhang,Lipeng Fan,Fangyuan Li,Zixue Sun,Chenming Zhang,Rubing Chen
Medicine. 2020; 99(43): e22662
[Pubmed] | [DOI]
30 Long-term testosterone undecanoate replacement therapy: Impact of ethnicity
Punith Kempegowda,Lauren M. Quinn,Joht Singh Chandan,Lisa Shepherd,Samina Kauser,Asad Rahim,Andrew Bates
Clinical Endocrinology. 2020;
[Pubmed] | [DOI]
31 Effects of pharmacologically induced Leydig cell testosterone production on intratesticular testosterone and spermatogenesis†
Jin-Yong Chung,Sean Brown,Haolin Chen,June Liu,Vassilios Papadopoulos,Barry Zirkin
Biology of Reproduction. 2019;
[Pubmed] | [DOI]
32 Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance
Chloe S Chaudhury,Thomas Mee,Cheryl Chairez,Mary McLaughlin,Rachel Silk,Chloe Gross,Sarah Kattakuzhy,Elana Rosenthal,Shyam Kottilil,Takara L Stanley,Colleen Hadigan
Clinical Infectious Diseases. 2019;
[Pubmed] | [DOI]
33 Obesity and male hypogonadism: Tales of a vicious cycle
David F. Carrageta,Pedro F. Oliveira,Marco G. Alves,Mariana P. Monteiro
Obesity Reviews. 2019;
[Pubmed] | [DOI]
34 Obesity’s role in secondary male hypogonadism: a review of pathophysiology and management issues
Omar Seyam,Jason Gandhi,Gunjan Joshi,Noel L. Smith,Sardar Ali Khan
SN Comprehensive Clinical Medicine. 2019;
[Pubmed] | [DOI]
35 The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism
Yu Seob Shin,Jong Kwan Park
Journal of Clinical Medicine. 2019; 8(2): 209
[Pubmed] | [DOI]
36 The Therapeutic Effects of Traditional Chinese Medicine for Poor Semen Quality in Infertile Males
Shu-Chiu Wang,Shu-Chen Wang,Chia-Jung Li,Ching-Heng Lin,Hsiao-Lin Huang,Liang-Miin Tsai,Chiung-Hung Chang
Journal of Clinical Medicine. 2018; 7(9): 239
[Pubmed] | [DOI]
37 Dynamics of testosterone levels in patients with newly detected glucose abnormalities and acute myocardial infarction
Anne Wang,Stefan Arver,John Flanagan,Viveca Gyberg,Per Näsman,Viveca Ritsinger,Linda G Mellbin
Diabetes and Vascular Disease Research. 2018; 15(6): 511
[Pubmed] | [DOI]
38 Absenteeism and Indirect Economic Burden Associated With Primary and Secondary Hypogonadism
Zsolt Hepp,Gilwan Kim,Gregory Lenhart,Barbara H. Johnson
Journal of Occupational and Environmental Medicine. 2018; 60(8): 724
[Pubmed] | [DOI]
39 Neural and Endocrinal Pathobiochemistry of Vitiligo: Comparative Study for a Hypothesized Mechanism
Mohamed-I. Kotb El-Sayed,Ahmed A. Abd El-Ghany,Refaat R. Mohamed
Frontiers in Endocrinology. 2018; 9
[Pubmed] | [DOI]
40 Identification and Structural Elucidation of New Process Impurity in Testosterone
Vandana Gupte,Umesh Luthra,Neetin Desai
Journal of Chromatographic Science. 2018;
[Pubmed] | [DOI]
41 A holistic review on the autoimmune disease vitiligo with emphasis on the causal factors
Seema Patel,Abdur Rauf,Haroon Khan,Biswa Ranjan Meher,Syed Shams ul Hassan
Biomedicine & Pharmacotherapy. 2017; 92: 501
[Pubmed] | [DOI]
42 Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era
Oluwatosin O. Ogedengbe,Edwin C. S. Naidu,Onyemaechi O. Azu
European Journal of Drug Metabolism and Pharmacokinetics. 2017;
[Pubmed] | [DOI]
43 Is Hypogonadism the Cause of Penile Self-Amputation in a Patient with Prior Testes Self-Mutilation?
Vinícius M. Cavalcante,Carlos G. Westin,João P. Fantin,José Gonçalves Filho,Márcio Gatti,Ana P. Bogdan,Jose G. Arruda,Pedro F. Arruda,Luis C. Spessoto,Thiago Antoniassi,Fernando N. Fácio
Urologia Journal. 2017; : uj.5000265
[Pubmed] | [DOI]
44 In Search for a Common Pathway for Health Issues in Men - the Sign of a Holmesian Deduction
Fouad Aoun,Anthony Kallas Chemaly,Simone Albisinni,Marc Zanaty,Thierry Roumeguere
Asian Pacific Journal of Cancer Prevention. 2016; 17(1): 1
[Pubmed] | [DOI]
45 Emerging medication for the treatment of male hypogonadism
Aydogan Aydogdu,Ronald S. Swerdloff
Expert Opinion on Emerging Drugs. 2016; 21(3): 255
[Pubmed] | [DOI]
46 Osteoporotic Vertebral Fractures as Part of Systemic Disease
Ling Oei,M. Carola Zillikens,Fernando Rivadeneira,Edwin H.G. Oei
Journal of Clinical Densitometry. 2016; 19(1): 70
[Pubmed] | [DOI]
47 Get to know “low T”
Kim Anne Pickett
Nursing Made Incredibly Easy!. 2016; 14(6): 30
[Pubmed] | [DOI]
48 Evaluation and treatment of male hypogonadism in primary care
Kim Anne Pickett
The Nurse Practitioner. 2016; 41(8): 1
[Pubmed] | [DOI]
49 Androgen receptor-related diseases: what do we know?
G. C. Shukla,A. R. Plaga,E. Shankar,S. Gupta
Andrology. 2016; : n/a
[Pubmed] | [DOI]
50 The Nanochannel Delivery System for Constant Testosterone Replacement Therapy
Silvia Ferrati,Eugenia Nicolov,Erika Zabre,Thomas Geninatti,Beverly A. Shirkey,Lee Hudson,Sharath Hosali,Michael Crawley,Mohit Khera,Ganesh Palapattu,Alessandro Grattoni
The Journal of Sexual Medicine. 2015; 12(6): 1375
[Pubmed] | [DOI]
51 Serum Biomarkers of Exposure to Perfluoroalkyl Substances in Relation to Serum Testosterone and Measures of Thyroid Function among Adults and Adolescents from NHANES 2011–2012
Ryan Lewis,Lauren Johns,John Meeker
International Journal of Environmental Research and Public Health. 2015; 12(6): 6098
[Pubmed] | [DOI]
52 On Treating Athletes with Banned Substances: The Relationship Between Mild Traumatic Brain Injury, Hypopituitarism, and Hormone Replacement Therapy
Sarah Malanowski,Nicholas Baima
Neuroethics. 2014;
[Pubmed] | [DOI]
53 Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats
A. Nahata,V. K. Dixit
Andrologia. 2012; 44: 396
[Pubmed] | [DOI]
54 Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats
Nahata A, Dixit VK
Andrologia. 2011;


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Classification o...
    Role of Testosterone
    Treatment Options

 Article Access Statistics
    PDF Downloaded2075    
    Comments [Add]    
    Cited by others 54    

Recommend this journal